Company Overview
Snapshot
Founded in June 2015 by Giora Weisz, Ron Davidson, Sigal Eli, and Eyal Teichman, Filterlex Medical operates with 1–10 employees. The company has raised $19.49M across 9 funding rounds from 4 investors. In May 2022, Filterlex Medical announced positive results from a first-in-human study for its CAPTIS full-body embolic protection device.
Business overview
Filterlex Medical is a medical device startup focused on developing the Captis, a full-body embolic protection device. This device is designed for easy and intuitive deployment and retrieval, securely positioning itself in the aorta to protect its surface during TAVI procedures. Its triple-action design provides full-body embolic protection by deflecting, capturing, and removing embolic particles without requiring additional access or interfering with the procedure workflow. The company operates within the Health Tech & Life Sciences sector, specifically targeting the Medical Devices and Medical Treatment & Therapeutics categories, serving healthcare providers.
Strategic signal
In May 2022, Filterlex Medical announced positive results from a first-in-human study for its CAPTIS full-body embolic protection device. This milestone is significant as it validates the device's safety and efficacy in a clinical setting, indicating strong progress towards commercialization and offering a promising solution for reducing embolic events during cardiovascular procedures. For investors, this signals a de-risking event and potential for future market entry and adoption in the cardiovascular medical device market.
Log in to access full profile ›Company Intelligence Q&A
- What is Filterlex Medical's primary product?
- Filterlex Medical's primary product is the Captis, a full-body embolic protection device designed to prevent embolic particles from causing strokes during cardiovascular procedures.
- When was Filterlex Medical founded?
- Filterlex Medical was founded in June 2015.
- What was a key clinical development for Filterlex Medical in 2022?
- In May 2022, Filterlex Medical announced positive results from a first-in-human study for its CAPTIS full-body embolic protection device, indicating successful clinical validation.
- What significant funding did Filterlex Medical receive in December 2021?
- In December 2021, Filterlex Medical was selected to receive funding from the European Innovation Council.